Table 2.
Effect of fibrates on homocysteine concentration (mean ± standard deviation, unless otherwise noted)
| Study | N | treatment Fenofibrate | tHcy before | tHcy after | % change | P |
|---|---|---|---|---|---|---|
| de Lorgeril 1999 | 29 | 200 mg/d,12 weeks | 11.4 ± 3.5 | 16.6 ± 5.2 | + 56 % | <0.001 |
| Dierkes 1999 | 10 | 200 mg/d, 6 weeks | 13.1 | 20.0 | + 44 (.8 ± 85) %b | a<0.001 |
| Landray 1999 | 8 | according to renal failure, 8 weeks | 15.1 | 21.8 | + 44 % | ap = 0.03 |
| Giral 2001 | 29 | 200 mg/d, 6 months | 12.3 ± 3.9 | 16.2 ± 4.6 | + 32 % | <0.001 |
| Bissonnette 2001 | 20 | 200 mg/d, 8 weeks | 10.3 ± 3.3 | 14.1 ± 3.8 | + 37 % | <0.001 |
| Dierkes 2001 | 25 | 200 mg/d, 6 weeks | 10.7 | 14.0 | 44 ± 47 %b | a<0.001 |
| Westphal 2001 | 22 | 200 mg/d, 6 weeks | 10.7 | 14.4 | + 35 % | a<0.001 |
| Stulc 2001 | 11 | 200 mg/d, 9 weeks | 12.3 ± 3.2 | 19.1 ± 7.2 | + 55 % | <0.001 |
| Melenovsky 2002 | 15 | 200 mg/d, 10 weeks | 12.4 ± 2.7 | 16.9 ± 3.7 | + 36 % | <0.001 |
| Melenovsky 2003 | 19 | 200 mg/d, 65 ± 18 days | 11.5 ± 3.0 | 17.5 ± 6.5 | + 52 % | not provided |
| Mayer 2003 | 24 | 200 mg/d, 3 months | 10.0 ± 2.9 | 14.2 ± 2.9 | + 42 % | not provided |
| Milionis 2003 | 22 | 200 mg/d, 12 weeks | 10.3 ± 3.3 | 14.2 ± 3.6 | + 38 % | <0.001 |
| Genest 2004 | 418 | 200 mg/d, 3 years | 11.0 ± 5.6 | 16.5 ± 10.7 | + 55 % | <0.001 |
| DAIS-Study | ||||||
| Bezafibrate | ||||||
| Dierkes 1999 | 10 | 400 mg/d, 6 weeks | 11.9 | 15.5 | +17 (.14 .65) %b | ap = 0.02 |
| Jonkers 1999 | 16 | 400 mg/d, 6 weeks | 11.9 ± 2.1 | 14.1 ± 2.9 | + 18 % | <0.001 |
| Harats 2001 | 12 | 400 mg/d, 6 weeks | 8.2 ± 2.3 | 6.8 ± 1.4 | −17 % | p = 0.22 |
| Ciprofibrate | ||||||
| Harats 2001 | 26 | 100 mg/d, 12 weeks | 6.8 ± 1.8 | 10.6 ± 4.3 | + 56 % | <0.0001 |
| Gemfibrozil | ||||||
| Westphal 2001 | 22 | 900 mg/d, 6 weeks | 12.9 | 12.4 | −4 % | aNS |
| Syvänne 2004 | ||||||
| LOCAT-Study | 395 | 900 mg/d, 16 months | 12.6 | 14.1 | + 11.9% | a<0.0001 |
Notes: Median;
calculated from individual data.
Abbreviations: ACE inhibitor, angiotensin-converting enzyme inhibitor; BIP, bezafibrate Infarction Prevention; CAD, coronary artery disease; CI, confidence interval; CVD, cardiovascular disease; DAIS, Diabetes Atherosclerosis Intervention Study; FIELD, Fenofibrate Intervention and Event Lowering in Diabetes; GFR, glomerular filtration rate; FA, folic acid; HCT, hydrochlorothiazide; LOCAT, Lopid Coronary Angiography Trial; MTHFR, methylenetetrahydrofolate reductase; PPARα, peroxisome-proliferation activated receptor alpha; PUFA, polyunsaturated fatty acids; RR, relative risk; homocysteine, total homocysteine.